Application of TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein in preparation of medicament for treating diabetic peripheral neuropathy

A technology for peripheral neuropathy and fusion protein, which can be used in nervous system diseases, drug combinations, peptide/protein components, etc., and can solve problems such as no related reports.

Inactive Publication Date: 2014-03-26
JINSHAN HOSPITAL FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant report on the use of TNF-α receptor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein in preparation of medicament for treating diabetic peripheral neuropathy
  • Application of TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein in preparation of medicament for treating diabetic peripheral neuropathy
  • Application of TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein in preparation of medicament for treating diabetic peripheral neuropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] The specific implementation manners provided by the present invention will be described in detail below with reference to the accompanying drawings.

[0027] 1. Experimental materials

[0028] Experimental animals: 6-week-old (140-160g) Wistar rats, 60 males, purchased from the Animal Center of Shanghai Medical College, Fudan University. The use of animals complies with the regulations of Shanghai Municipal Animal Management Committee. Raise in single cage, keep the rearing room quiet, keep the temperature at 20±2℃, relative humidity at 60%, light time 12h / day, clean drinking water, standard feeding before modeling.

[0029] Clean-grade rat ordinary maintenance feed, purchased from the Animal Center of Shanghai Medical College of Fudan University; high-fat, high-sugar feed, that is, add 10% lard and 20% sucrose to the clean-grade rat ordinary maintenance feed , After mixing and drying, irradiate and sterilize.

[0030] Rabbit anti-rat MBP monoclonal antibody, purchased from S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein, including application of TNF-alpha receptor-antibody fusion protein in preparation of medicaments for treating diabetic peripheral neuropathy (DPN), delaying diabetic peripheral neuropathy and increasing nerve conduction velocity or relieving nerve demyelination. The application provided by the invention has the advantages that the TNF-alpha receptor-antibody fusion protein is applied to a DPN rat model to inhibit the function of TNF-alpha, and the influences of the TNF-alpha receptor-antibody fusion protein on the nerve conduction velocity of a DPN rat, nervous tissue pathological alteration and myelin basic protein expression are observed, so that the action of the TNF-alpha in the pathogenesis of the DPN is made clear, and the effects of the TNF-alpha receptor-antibody fusion protein in delaying the development of peripheral neuropathy of the DPN rat, improving the expression of sciatic nerve morphology of the DPN rat and relieving demyelination of sciatic nerve are proved. Thus, the TNF-alpha receptor-antibody fusion protein has a wide application prospect in the preparation of medicaments for treating diabetic peripheral neuropathy.

Description

Technical field [0001] The invention relates to the use of a cytokine TNF-α receptor-antibody fusion protein, specifically, the application of the TNF-α receptor-antibody fusion protein in the preparation of drugs for treating diabetic peripheral neuropathy. Background technique [0002] Diabetes is a common chronic metabolic disease and one of the most prevalent diseases in the world. With the rapid development of social economy, changes in people's lifestyles and the aging of the population, the incidence of diabetes is increasing year by year. According to statistics, the number of diabetic patients in the world has exceeded 100 million. With the increase in the incidence of diabetes, the incidence of diabetic neuropathy is also increasing. Diabetic neuropathy can be divided into the following categories according to neuroanatomy: peripheral neuropathy, autonomic neuropathy, cranial neuropathy, spinal cord pathology and brain pathology. Among them, diabetic peripheral neurop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P3/10A61P25/02A61P25/00
Inventor 陈英辉施晓红许国雄李炳陈碧琴
Owner JINSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products